<DOC>
	<DOCNO>NCT00250926</DOCNO>
	<brief_summary>The purpose study find combination bortezomib ( Velcade ) , dexamethasone ( Decadron ) rituximab ( Rituxan ) effective treat Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Study Combination Bortezomib , Dexamethasone , Rituximab Patients With Waldenstroms Macroglobulinemia</brief_title>
	<detailed_description>- This open-label study mean patient doctor know drug dose patient receive throughout study . - Patients receive 8 cycle study treatment bortezomib , dexamethasone rituximab . Each cycle 21 day long . Therapy give first , fourth , eighth eleventh day cycle , follow 10 day rest period . The first 4 cycle give one . Three month complete fourth cycle therapy , patient receive one cycle therapy every three month total four cycle . - On first , fourth , eighth eleventh day cycle , patient receive bortezomib dexamethasone intravenous injection needle vein . On eleventh day , patient also receive rituximab intravenous infusion get bortezomib dexamethasone . - Prior infusion rituximab therapy , patient ask take medication prevent reduce side effect rituximab . These medication benadryl , tylenol , possibly steroid . The doctor determine drug appropriate individual patient . - During rituximab infusion , patient blood pressure pulse monitor frequently infusion rate may decrease depend upon side effect experience . - After therapy complete , patient follow every three month 2 year office visit laboratory test determine well therapy continue benefit .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Clinicopathological diagnosis Waldenstrom 's macroglobulinemia ( WM ) No previous therapy WM Measurable disease , define presence immunoglobulin M ( IgM ) paraprotein minimum IgM level great equal 2 time upper limit institution 's normal value CD20 positive disease base previous bone marrow immunohistochemistry flow cytometric analysis perform 3 month prior enrollment Karnofsky performance status &gt; 60 Life expectancy &gt; 3 month AST ( SGOT ) &lt; 3 x ULN ALT ( SGPT ) &lt; 3 x ULN Total bilirubin &lt; 2 x ULN Calculated measure creatinine clearance &gt; 30mL/minute Serum sodium &gt; 130 mmol/L Female subject either postmenopausal surgically sterilize willing use acceptable method birth control Male subject agree use acceptable method contraception duration study Previous therapy Waldenstrom 's macroglobulinemia Myocardial infarction within 6 month prior enrollment New York Hospital Association Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Hypersensitivity dexamethasone , boron mannitol Pregnant breastfeed woman Serious medical psychiatric illness likely interfere participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>bortezomib</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>rituximab</keyword>
</DOC>